Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06283550 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hand Eczema

Interventions

DRUG: Abrocitinib 200 mg
DRUG: Abrocitinib 100 mg
DRUG: Placebo

Sponsor

Innovaderm Research Inc.